Early-Stop trial tests new drug combo for tough pancreatic cancer

NCT ID NCT05417386

Summary

This study tested whether adding an experimental drug called NIS793 to a standard chemotherapy combination (FOLFIRINOX) could help people with metastatic pancreatic cancer. The goal was to see if the new combination was safe and could help shrink tumors enough for surgery. The trial was terminated early after enrolling only 4 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

Conditions

Explore the condition pages connected to this study.